SGS implements Veeva Vault clinical trial management system across its global network
![](/46/pdcnewsitem/07/77/95/SGS-implements-Veeva-Vault-clinical-trial-management-system-across-its-global-network.jpeg)
Will improve operational efficiency and drive faster, higher-quality trial execution.
SGS will implement the Veeva Vault CTMS (clinical trial management system) across its network of clinical operations sites for the management of its global clinical study services.
Vault CTMS will enable SGS to share state-of-the-art reporting capabilities with its clients and deliver greater flexibility in running studies. Together with Veeva Vault eTMF (electronic trial master file), SGS will drive greater harmonization across its clinical operations. SGS will begin running studies on Vault CTMS in spring 2019, with any current studies scheduled to end after June 2019 being migrated to the new system.
“Veeva Vault CTMS, along with Veeva Vault eTMF will allow us to streamline our clinical trial management and improve decision-making within our planning and operations teams across the Americas and Europe,” commented Janelle Johnson, SGS International Project Management Director. “SGS is committed to investing where necessary to maintain its leadership position in clinical research, and ensuring it has the most efficient systems, and in-turn, offer the highest level of service and experience to our clients.”
“Veeva Vault CTMS will enable SGS to improve its operational efficiency and drive faster, higher-quality trial execution,” added Henry Galio - Senior Director, Veeva Vault CTMS. Now clinicians and managers can have greater oversight and improved decision-making capabilities during studies”.
![SGS](https://www.cphi-online.com/th247924-comp247924.png)
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance